JP2021534220A5 - - Google Patents

Info

Publication number
JP2021534220A5
JP2021534220A5 JP2021510094A JP2021510094A JP2021534220A5 JP 2021534220 A5 JP2021534220 A5 JP 2021534220A5 JP 2021510094 A JP2021510094 A JP 2021510094A JP 2021510094 A JP2021510094 A JP 2021510094A JP 2021534220 A5 JP2021534220 A5 JP 2021534220A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
variable region
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534220A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047728 external-priority patent/WO2020041604A1/en
Publication of JP2021534220A publication Critical patent/JP2021534220A/ja
Publication of JP2021534220A5 publication Critical patent/JP2021534220A5/ja
Priority to JP2024119250A priority Critical patent/JP7818042B2/ja
Pending legal-status Critical Current

Links

JP2021510094A 2018-08-22 2019-08-22 抗her2ポリペプチド及びそれらの使用の方法 Pending JP2021534220A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024119250A JP7818042B2 (ja) 2018-08-22 2024-07-25 抗her2ポリペプチド及びそれらの使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721505P 2018-08-22 2018-08-22
US62/721,505 2018-08-22
PCT/US2019/047728 WO2020041604A1 (en) 2018-08-22 2019-08-22 Anti-her2 polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024119250A Division JP7818042B2 (ja) 2018-08-22 2024-07-25 抗her2ポリペプチド及びそれらの使用の方法

Publications (2)

Publication Number Publication Date
JP2021534220A JP2021534220A (ja) 2021-12-09
JP2021534220A5 true JP2021534220A5 (https=) 2022-08-23

Family

ID=67989062

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510094A Pending JP2021534220A (ja) 2018-08-22 2019-08-22 抗her2ポリペプチド及びそれらの使用の方法
JP2024119250A Active JP7818042B2 (ja) 2018-08-22 2024-07-25 抗her2ポリペプチド及びそれらの使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024119250A Active JP7818042B2 (ja) 2018-08-22 2024-07-25 抗her2ポリペプチド及びそれらの使用の方法

Country Status (15)

Country Link
US (1) US20220002436A1 (https=)
EP (1) EP3840781A1 (https=)
JP (2) JP2021534220A (https=)
KR (1) KR20210074279A (https=)
CN (1) CN113286610A (https=)
AR (1) AR115998A1 (https=)
AU (2) AU2019326545A1 (https=)
BR (1) BR112021002953A2 (https=)
CA (1) CA3141815A1 (https=)
EA (1) EA202190603A1 (https=)
IL (2) IL326298A (https=)
MX (1) MX2021001976A (https=)
SG (1) SG11202101436SA (https=)
TW (1) TW202017947A (https=)
WO (1) WO2020041604A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
BR112021015656A2 (pt) 2019-02-20 2021-10-05 Denali Therapeutics Inc. Anticorpos anti-trem2 e métodos de uso dos mesmos
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
AU2021224200A1 (en) * 2020-02-19 2022-09-08 Denali Therapeutics Inc. Engineered anti-HER2 bispecific proteins
EP4229192A1 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
WO2023038803A2 (en) * 2021-08-25 2023-03-16 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
WO2023128702A1 (ko) * 2021-12-31 2023-07-06 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
EP4631975A1 (en) * 2022-12-08 2025-10-15 Adel Inc. Fusion comprising anti-tau antibody and peptide and use thereof
CN120648654A (zh) * 2024-03-13 2025-09-16 深圳太力生物技术有限责任公司 重组细胞的制备方法、重组细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1699826B1 (en) * 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
HUE045144T2 (hu) * 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
WO2015191934A2 (en) * 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
CN107531788B (zh) * 2015-06-24 2022-06-21 豪夫迈·罗氏有限公司 对her2和血脑屏障受体特异性的三特异性抗体及使用方法
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
CN110506055A (zh) * 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
EP3665194A4 (en) * 2017-08-10 2021-07-07 Denali Therapeutics Inc. AFFINITY BASED METHODS OF USING TRANSFERRIN RECEPTOR BINDING PROTEINS

Similar Documents

Publication Publication Date Title
JP2021534220A5 (https=)
JP2024150674A5 (https=)
JP7793679B2 (ja) ヒトTim-3に対するモノクローナル抗体
JP2021510162A5 (https=)
JP2021533779A5 (https=)
CN106414494B (zh) 具有促凋亡活性的人IgG1衍生的抗体
RU2015145719A (ru) Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
JP2022524588A5 (https=)
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
JP2021534220A (ja) 抗her2ポリペプチド及びそれらの使用の方法
JP2023139025A (ja) 二重特異性抗原結合コンストラクト
JP2022521305A (ja) 抗pd-l1抗体及びその使用
TW201934578A (zh) 治療方法
AU2022317124B2 (en) Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
JP2022514615A (ja) ヒト免疫チェックポイントCEACAM1(CD66a)に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法
JP2025527160A (ja) 多重特異性抗体およびその使用
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
US20250376536A1 (en) Multispecific anti-cd40 / anti-fap antibodies and uses thereof
RU2777336C1 (ru) Моноклональные антитела к tim-3 человека
US20220153869A1 (en) Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
JP2026513915A (ja) ヒンジが修飾された二重特異性抗体
HK40123160A (zh) 抗pd-1-抗vegfa的双特异性抗体的医药用途
TW202519261A (zh) 用於治療癌症之結合γ-δ T細胞受體之抗體
RU2022103028A (ru) Антитела против рецептора программируемой смерти pd-1 человека
HK40043135B (zh) 针对人tim-3的单克隆抗体